genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models
genOway acquires additional rights to develop all animal cell models using the CRISPR/Cas9 system LYON, France, Jan. 7, 2020 /PRNewswire/ -- genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic ...
Merck and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models
- genOway to acquire exclusive rights to Merck's foundational genome-editing
patents to produce, sell rodent models
- New technologies and solutions to be developed using CRISPR/Cas9 to
accelerate delivery of better drugs to patients
DARMSTADT, Germany, Dec. 11, 2018 /PRNewswire/ -- Merck
